CO116 Real-World Treatment Patterns, Healthcare Resource Use and Hospital Provider Cost of Recently Approved Treatments for Adult Relapsed or Refractory Acute Lymphoblastic Leukemia in the US: Blinatumomab and/or Inotuzumab Ozogamicin
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.189
https://www.valueinhealthjournal.com/article/S1098-3015(23)00289-9/fulltext
Title :
CO116 Real-World Treatment Patterns, Healthcare Resource Use and Hospital Provider Cost of Recently Approved Treatments for Adult Relapsed or Refractory Acute Lymphoblastic Leukemia in the US: Blinatumomab and/or Inotuzumab Ozogamicin
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00289-9&doi=10.1016/j.jval.2023.03.189
First page :
Section Title :
Open access? :
No
Section Order :
11346